These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 459012)

  • 21. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rate of survival in prostatic cancer with bone metastasis].
    Kuntz D; Ryckewaert A
    Rev Fr Etud Clin Biol; 1969; 14(6):609-13. PubMed ID: 5824263
    [No Abstract]   [Full Text] [Related]  

  • 23. [Retrospective clinical evaluation of prognosis factors in stage D2 prostatic cancer treated with endocrine therapy].
    Kudo K; Nagata M; Hayashi N; Imamura H; Kimura M; Mimura H; Matsuyama K; Shishido S; Chino I
    Hinyokika Kiyo; 1991 Feb; 37(2):129-34. PubMed ID: 1710871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A multimodal treatment of prostatic carcinoma and the 5-year survival rate].
    Maruoka M; Miyauchi T; Nagayama T
    Hinyokika Kiyo; 1989 Jan; 35(1):57-63. PubMed ID: 2729020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should we treat localized prostate cancer? An opinion.
    Menon M; Parulkar BG; Baker S
    Urology; 1995 Nov; 46(5):607-16. PubMed ID: 7495109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
    Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
    Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate.
    Oefelein MG; Smith ND; Grayhack JT; Schaeffer AJ; McVary KT
    J Urol; 1997 Oct; 158(4):1460-5. PubMed ID: 9302143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.
    Halabi S; Vogelzang NJ; Ou SS; Small EJ
    J Urol; 2007 Feb; 177(2):531-4. PubMed ID: 17222627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population based study of hormonal therapy and survival in men with metastatic prostate cancer.
    Lu-Yao G; Moore DF; Oleynick JU; DiPaola RS; Yao SL
    J Urol; 2007 Feb; 177(2):535-9. PubMed ID: 17222628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting survival of patients with node-positive prostate cancer following multimodal treatment.
    Abdollah F; Karnes RJ; Suardi N; Cozzarini C; Gandaglia G; Fossati N; Bianchi M; Boorjian SA; Sun M; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2014 Mar; 65(3):554-62. PubMed ID: 24094576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
    Osunkoya AO; Epstein JI
    Am J Surg Pathol; 2007 Sep; 31(9):1323-9. PubMed ID: 17721186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.
    Muralidhar V; Dinh KT; Mahal BA; Ziehr DR; Chen YW; Viswanathan VB; Nezolosky MD; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Trinh QD; Nguyen PL
    Urol Oncol; 2015 Jul; 33(7):330.e19-25. PubMed ID: 25990612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical analysis of 169 patients with prostate cancer].
    Okaneya T; Mizusawa H; Yoneyama T; Taguchi I; Komiyama I; Kawakami M; Hosaka K; Tsuruta T; Murata Y; Komatsu H; Misawa K; Kiyokawa H
    Hinyokika Kiyo; 1996 Aug; 42(8):563-7. PubMed ID: 8889563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical study on adenocarcinoma of the prostate].
    Yamamoto A; Yuasa M; Imagawa A; Kagawa S; Kurokawa K
    Hinyokika Kiyo; 1987 Dec; 33(12):2050-4. PubMed ID: 3448932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcome for lymph node-positive prostate cancer.
    Swanson GP; Riggs MW; Herman M
    Prostate Cancer Prostatic Dis; 2008; 11(2):198-202. PubMed ID: 17519924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
    Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
    Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality.
    Bismar TA; Dolph M; Teng LH; Liu S; Donnelly B
    Eur J Cancer; 2012 Mar; 48(4):538-46. PubMed ID: 22300588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient treatment preference in metastatic prostate cancer.
    Creagh T
    Ir Med J; 1996; 89(1):12. PubMed ID: 8984072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New concepts in the treatment of stage D1 adenocarcinoma of the prostate.
    Austenfeld MS; Davis BE
    Urol Clin North Am; 1990 Nov; 17(4):867-84. PubMed ID: 2219583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.